News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
AstraZeneca PLC’s Recentin Flunks Colon Cancer Tests
May 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, May 28 (Reuters) - AstraZeneca (AZN.L) dropped plans to file experimental cancer drug Recentin as a first-line treatment for colon cancer on Friday after disappointing results from a second pivotal clinical trial with the medicine.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Insights
JPM26: As Capital Concentrates, VCs Scrutinize Founder Pedigree and CEO Fit in Early Biotech
January 15, 2026
·
2 min read
·
Jennifer Smith-Parker
Opinion
Trump Must Make Biotech Innovation a National Priority
January 14, 2026
·
7 min read
·
Cyriac Roeding
Business
JPM26: Lilly Plots Path to Dominance as Obesity Market Enters a New Era
January 14, 2026
·
2 min read
·
Nick Paul Taylor
Podcast
Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
January 14, 2026
·
2 min read
·
Heather McKenzie
